Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia

By Luo Xiaochuang   Feng Maoxiao   Zhu Xuejiao   Li Yumin   Fei Jia   Zhang Yuan  

Hematology, Vol. 18, Iss. 6, 2013-11 ,pp. : 333-339

Maney Publishing

Access to resources Recommend Favorite

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

By Giles F.J.   Feldman E.J.   Roboz G.J.   Larson R.A.   Mamus S.W.   Cortes J.E.   Verstovsek S.   Faderl S.   Talpaz M.   Beran M.   Albitar M.   O'Brien S.M.   Kantarjian H.M.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1091-1096

Elsevier

Access to resources Recommend Favorite

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

By Bornhauser Martin   Jenke Andreas   Freiberg-Richter Jens   Radke Jörgen   Schuler Ulrich   Mohr Brigitte   Ehninger Gerhard   Schleyer Eberhard  

Annals of Hematology, Vol. 83, Iss. 6, 2004-06 ,pp. : 401-402

Springer Publishing Company

Access to resources Recommend Favorite

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

By Galanopoulos A.  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 281-282

Springer Publishing Company

Access to resources Recommend Favorite